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Summary
Background People with dementia die prematurely. Identifying differences in mortality rates between different types 
of dementia might aid in the development of preventive interventions for the most vulnerable populations. The aim 
of this study was to compare the difference in mortality rates between individuals without dementia and individuals 
with various types of dementia.
Methods For this systematic review and meta-analysis, we did a systematic search of MEDLINE, PubMed, Embase, and 
Cochrane Library from inception to July 11, 2020, for cross-sectional or cohort studies that assessed mortality and 
survival-related outcomes among people with different types of dementia compared with people without dementia. 
Single-arm studies without comparison groups and autopsy studies or family studies that used a selected sample were 
excluded. The Newcastle-Ottawa Scale was used by two authors (D-JL and C-SC) independently to measure the 
methodological quality of included studies, and two authors (F-CY and P-TT) independently extracted data. We 
assessed differences in all-cause mortality rate and survival time from dementia diagnosis between individuals without 
dementia, individuals with Alzheimer’s disease, and individuals with non-Alzheimer’s disease dementias. The 
secondary outcomes were age at death and survival time from disease onset. Random-effects meta-analyses were done. 
Effect sizes included hazard ratios (HRs) and mean differences (MDs) with 95% CIs. Potential moderators, including 
age-associated moderators, were identified through meta-regression and subgroup analyses. This study is registered 
with PROSPERO, CRD42020198786.
Findings Our database search identified 11 973 records, and we included 78 eligible studies in our analyses, encompassing 
63 125 individuals with dementia and 152 353 controls. Individuals with any type of dementia had a higher mortality rate 
than individuals without dementia (HR 5·90, 95% CI 3·53 to 9·86), and the HR for all-cause mortality was highest for 
Lewy body dementia (17·88, 5·87 to 54·46). After diagnosis, the mean survival time for people with Alzheimer’s disease 
was 5·8 years (SD 2·0). Compared with people with Alzheimer’s disease, a diagnosis of any non-Alzheimer’s disease 
dementia was associated with a higher risk of all-cause mortality (HR 1·33, 1·21 to 1·46), a shorter survival time from 
diagnosis (MD –1·12 years, 95% CI –1·52 to –0·72), and a younger age at death (–1·76 years, –2·66 to –0·85). Survival 
time from disease onset was also shorter in people with non-Alzheimer’s dementia, across types, compared with people 
with Alzheimer’s disease, but the subgroup analysis revealed that this difference was only significant for vascular 
dementia (MD –1·27 years, –1·90 to –0·65) and dementia with Lewy bodies (MD –1·06 years, –1·68 to –0·44). The 
interactions between age and several survival-related outcomes were significant. 39 (50%) of the 78 included studies 
were rated as good quality, and large heterogeneity (I²>75%) was observed for most of the study outcomes.
Interpretation Alzheimer’s disease is the most common type of dementia and one of the major causes of mortality 
worldwide. However, the findings from the current study suggest that non-Alzheimer’s disease dementias were 
associated with higher morality rates and shorter life expectancy than Alzheimer’s disease. Developing tailored 
treatment and rehabilitation programmes for different types of dementia is important for mental health providers, 
patients, and their families.
Funding None.
Copyright © 2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 
4.0 license.
Introduction 
The prevalence of dementia, also classified as neuro­
cognitive disorder,1 has been increasing,2 and is one of the 
major causes of disability and dependency among older 
people worldwide.2 This results in high costs for health 
and social care systems,3 and people with dementia face 
substantial health challenges and might have at least twice 
as high a mortality risk as people without dementia.4,5
Differences in mortality rates across different types of 
dementia might affect prevalence rates and health­care 
service needs. Previous studies addressing life expectancy 
and survival have largely focused on Alzheimer’s disease. 
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The life expectancy is about 7–10 years in individuals 
diagnosed with Alzheimer’s disease in their 60s and early 
70s,6 but findings for other types of dementia have been 
inconsistent. For example, in some studies, people with 
vascular dementia were found to have a poorer prognosis 
and a shorter survival time after diagnosis than people 
with Alzheimer’s disease,7,8 whereas other studies have 
reported opposite findings.9,10 People with Parkinson’s 
disease dementia or dementia with Lewy bodies were 
found to have a three times higher risk of mortality 
compared with individuals without dementia,11 and 
people with dementia with Lewy bodies have also been 
shown to have poorer health outcomes and higher 
mortality rates compared with people with Alzheimer’s 
disease.12–14 However, several studies have found little 
differences in mortality between different dementia 
types.15,16
Studies on non­Alzheimer’s types of dementia have 
commonly used people with Alzheimer’s disease as a 
reference group, and considerable uncertainty exists 
regarding mortality rates in non­Alzheimer’s types of 
dementia compared with the individuals without 
dementia after controlling for confounders (eg, age and 
co­occurring medical conditions). Thus, a systematic 
review and meta­analysis might provide more robust 
evidence to inform treatment plans and advice to those 
affected. To our knowledge, there has been no meta­
analysis focusing on mortality rates across different types 
of dementias compared with the general population. The 
aim of this study was to compare mortality rates and 
other survival­related outcomes among individuals 
without dementia, people with Alzheimer’s disease, and 
people with non­Alzheimer’s dementias using a meta­
analysis to synthesise all available evidence.
Methods 
Search strategy and selection criteria 
This systematic review and meta­analysis followed 
the Preferred Reporting Items for Systematic Reviews 
and Meta­Analyses for Protocols (appendix pp 166–69).17
Research in context
Evidence before this study
Alzheimer’s disease is the most common form of dementia. 
Alzheimer’s disease was the sixth leading cause of death in the 
USA and the fifth leading cause of death among US Americans 
aged 65 years and older in 2019. However, differences in 
mortality rates between different types of dementia remain 
unknow. Previous studies addressing life expectancy and survival 
have largely focused on Alzheimer’s disease, but findings for other 
types of dementia have been inconsistent. Identifying differences 
in survival between different types of dementia might aid in the 
development of preventive interventions for these most 
vulnerable populations. To our knowledge, no meta-analyses 
have been done to examine mortality rates across different types 
of dementias compared with individuals without dementia. 
We searched MEDLINE, PubMed, Embase, and Cochrane Library 
for studies done in humans from database inception until 
July 11, 2020, for studies published in English that provided 
sufficient data on survival or mortality parameters for any types 
of dementia versus individuals without dementia or any 
non-Alzheimer’s types of dementia versus Alzheimer’s disease. 
The search terms used were: (“mortality” OR “death” OR 
“survival”) AND (“Alzheimer’s disease” OR “Frontotemporal 
dementia” OR “Frontotemporal lobar degeneration” OR 
“behavioral variant frontotemporal dementia” OR “dementia 
with Lewy body” OR “Lewy body” OR “Lewy bodies” OR “Lewy” 
OR “dementia with Lewy bodies” OR “LBD” OR “Parkinson’s 
disease dementia” OR “Parkinson’s disease dementia” OR 
“vascular dementia” OR “Arteriosclerotic Dementia” OR 
“Dementia Multi-Infarct”) AND (“normal cognition” OR 
“non-dementia” OR “control”). Specific database search terms are 
outlined in the appendix (p 170). We aimed to examine which 
type of dementia is associated with the highest mortality rate and 
the shortest survival. 
Added value of this study
To our knowledge, this study is the first systematic review and 
meta-analysis to compare mortality rates and survival 
outcomes between people with Alzheimer’s disease, people 
with non-Alzheimer’s dementias, and people without dementia 
based on all the available published evidence. 
We identified 78 studies encompassing 
63 125 individuals with dementia and 152 353 controls. We 
found that people with Lewy body dementia were associated 
with the highest all-cause mortality rate compared with 
individuals without dementia. The mean survival time was 
7·6 years from Alzheimer’s disease onset and 5·8 years from 
diagnosis. Compared with people with Alzheimer’s disease, 
people with non-Alzheimer’s dementias had higher mortality 
rates, shorter survival times from diagnosis, and younger ages 
at death. Although our meta-regression analyses identified 
several factors that moderated individual study findings, the 
change in point estimates of mortality rate was less than 10% 
when adjusted for potential moderators. Group differences 
between vascular dementia, Lewy body dementias, and 
frontotemporal lobe degeneration were not significant.
Implications of all the available evidence
Our findings suggest that Alzheimer’s disease has the most 
favourable survival-related outcomes compared with 
non-Alzheimer’s dementias, and Lewy body dementias have 
the highest mortality rates. Understanding differences in 
mortality between different types of dementia is important for 
both physicians and policy makers to develop tailored 
treatment and rehabilitation programmes and for patients and 
their families to facilitate future care planning. Future studies 
should explore risks and potential contributing factors affecting 
these differences between different types of dementia.
See Online for appendix
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From June 27 to July 11, 2020, two authors (D­JL and 
C­SC) independently searched MEDLINE, PubMed, 
Embase, and Cochrane Library for studies done in 
humans and published in English from database 
inception until July 11, 2020. To ensure 
comprehensiveness, we examined the reference lists 
from retrieved articles for supplementary relevant 
studies. The study was approved by the Institutional 
Review Board of the Tri­Service General Hospital 
(TSGHIRB: B­109–29).
The following eligibility criteria were applied: (1) cohort 
(prospective or retrospective) or cross­sectional studies 
reporting survival times from dementia diagnosis or 
onset, (2) studies with a baseline and follow­up evaluation, 
(3) studies with sufficient data on survival or mortality 
parameters for individuals with any type of dementia 
versus individuals without dementia or any non­
Alzheimer’s type of dementia versus individuals with 
Alzheimer’s disease, (4) studies using well established 
criteria for the diagnosis of dementia (appendix p 6), and 
(5) peer­reviewed studies written in English.
Studies were excluded if they were: (1) single­arm 
studies without any comparison groups (eg, general 
population or individuals with Alzheimer’s disease), (2) a 
selected sample from autopsy studies or family studies, 
precluding external generalisability, (3) review articles 
that did not provide original data, (4) case series or case 
reports, (5) conference or meeting abstracts, and (6) 
randomised controlled trials. 
Outcomes 
The main outcomes were the hazard ratio (HR) of 
all­cause mortality rate and mean difference (MD) in 
survival time from diagnosis. The survival time from 
diagnosis was the mean survival time (year) from 
diagnosis to death. The secondary outcomes were age at 
death and survival time from disease onset.
Data analysis 
Two authors (D­JL and C­SC) independently used the 
Newcastle­Ottawa Scale (NOS) to assess the quality of 
each included study.18 Disagreements were resolved 
through discussion with a third author (C­SL). Two authors 
(F­CY and P­TT) independently extracted data using a 
prespecified data extraction form. Disagreements were 
resolved through discussion with a third author (C­SL). 
Information extracted included patients’ characteristics 
(number of participants, age, sex, baseline mean scores on 
the Mini­Mental State Examination [MMSE], data on co­
occurring physical and mental illness, and medications), 
study characteristics (population, study design, year of 
publication, follow­up period, diagnostic criteria, and 
country), and data on the number of deaths, age at 
dementia diagnosis, age at disease onset, age at death, and 
survival time (year) from diagnosis and from disease 
onset. The present meta­analysis used summary estimates 
for analysis.
We first compared the HR for all­cause mortality of 
all dementia participants, across subtypes, with that of 
individuals without dementia, and then compared 
mortality risk and survival­related outcomes of 
individuals with non­Alzheimer’s types of dementia 
with outcomes of individuals with Alzheimer’s disease. 
We also did subgroup analyses to examine 
group differences in outcomes between vascular 
dementia, Lewy body dementia, frontotemporal 
degeneration, and Alzheimer’s disease. The subtypes of 
Lewy body dementia included Parkinson’s disease 
dementia, dementia with Lewy bodies, and Lewy body 
variant of Alzheimer’s disease, and the subtypes of 
frontotemporal degeneration included behavioural 
variant frontotemporal dementia, progressive non­fluent 
aphasia, semantic dementia, progressive supranuclear 
palsy, and corticobasal degeneration. The subtypes of 
Lewy body dementia and of frontotemporal degeneration 
were compared with Alzheimer’s disease for all 
outcomes, if at least two studies on the subtypes provided 
the data.
The pooled HR and MD with corresponding 95% CIs 
were calculated. If the HR of the Cox regression was not 
available in the original study, we estimated it using 
established methods.19 A random­effects model was used 
to account for heterogeneity. If two or more studies 
shared a control sample, the size of this sample was 
divided equally between these studies. Heterogeneity 
was assessed using the I² statistic, and a value exceeding 
75% implied a high heterogeneity.20 Publication bias was 
assessed using funnel plot asymmetry and Egger’s 
regression test.
We completed several pre­planned subgroup and meta­
regression analyses to examine potential moderators, 
namely, whether the study used a cohort versus non­
cohort design; MMSE score; proportion of female 
participants; sample size; proportion of diabetes, hyper­
tension, cerebrovascular accident, and cardiovascular 
disease; and NOS scores. Because age is an important 
risk factor of death, age needs to be considered a 
significant moderator for all the primary and secondary 
outcomes. Therefore, the effects of age­associated 
moderators were specifically examined, namely, age at 
onset and diagnosis and group differences in age at onset 
and diagnosis. For significant moderators, we calculated 
the proportion of change­in­estimate of the adjusted 
effect sizes against the raw effect sizes. When applicable, 
one­way sensitivity analyses were done by removing a 
single study at a time to determine the robustness of the 
findings.21 We also calculated the risk ratio (RR) of all­
cause mortality. The meta­regression and publication bias 
test was done when at least ten studies were available.22 
The threshold for statistical significance was set at a 
two­tailed p<0·05 for all analyses with the exception of 
p<0·1 for Egger’s regression test. Analyses were done 
using Stata version 16.0. This study is registered with 
PROSPERO, CRD42020198786.
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Role of the funding source 
There was no funding source for this study.
Results 
The database search identified 11 973 studies (figure 1). 
After reviewing the titles and abstract, we excluded 
11 511 studies that did not fulfil our inclusion criteria 
(appendix p 170). The remaining 462 studies were 
reviewed in full text, and 78 articles containing relevant 
data were included in our analysis (appendix p 6). The 
results of the primary and secondary outcomes are 
summarised in the appendix (p 19). We identified 
15 control samples (n=152 353) and 173 dementia samples 
(n=63 125): 78 Alzheimer’s disease samples (n=46 314), 
27 vascular dementia samples (n=10 799), 48 Lewy body 
dementia samples (n=4474), and 20 frontotemporal 
degeneration samples (n=1538). There were four Lewy 
body dementia samples with unspecified subtype (n=326) 
and 15 unspecified frontotemporal degeneration samples 
(n=1296). Among the subtypes of Lewy body dementia, 
there were four studies on Parkinson’s disease dementia 
(n=411), 28 studies on dementia with Lewy bodies 
(n=2794) and 12 studies on Lewy body variant of 
Alzheimer’s disease (n=943). Among the subtypes of 
frontotemporal degeneration, there were two studies on 
behavioural variant frontotemporal dementia (n=176) 
and three studies on semantic dementia (n=64). We 
excluded studies on progressive non­fluent aphasia 
(n=27), progressive supranuclear palsy (n=44), and 
corticobasal degeneration (n=15) because there was only 
one available sample in these subtypes of frontotemporal 
degeneration.
In people with any dementia type, the mean age at 
disease onset was 68·1 (SD 7·0) years, and mean age  was 
72·7 (5·9) years (table 1). HR estimates indicated a higher 
mortality rate in people with any dementia type than in 
individuals without dementia (5·90, 95% CI 3·53–9·86; 
figure 2). Compared with individuals without dementia, 
Lewy body dementia was associated with the highest HR for 
mortality (17·88, 5·87–54·46), followed by frontotemporal 
degeneration (15·26, 4·34–53·69), vascular dementia 
(5·03, 1·63–15·51), and Alzheimer’s disease (3·70, 
1·99–6·88). Group differences in mortality risk between 
Alzheimer’s disease, frontotemporal degeneration, Lewy 
body dementia, and vascular dementia were significant 
(p=0·04; appendix p 22).
In people with Alzheimer’s disease, the mean age at 
disease onset was 68·8 (6·7) years, and the mean age at 
diagnosis was 74·2 (5·7) years. Compared with 
Alzheimer’s disease, non­Alzheimer’s dementias, across 
types, were associated with a higher HR for mortality 
(HR 1·33, 95% CI 1·21–1·46; figure 3), whereas the 
differences between vascular dementia, Lewy body 
dementia, and frontotemporal degeneration were not 
significant (group difference: p=0·31; appendix p 24). 
Among the subtypes of Lewy body dementia, dementia 
with Lewy bodies was associated with the highest HR for 
mortality compared with Alzheimer’s disease (1·54, 
1·23–1·93; figure 3). Frontotemporal degeneration and 
its subtypes were not associated with a higher HR for 
mortality compared with Alzheimer’s disease. The forest 
plots showing the primary and secondary outcomes are 
shown in the appendix (pp 21–75).
The mean survival time from Alzheimer’s disease 
onset was 7·6 years (2·1) and the mean survival time from 
diagnosis was 5·8 years (2·0). The survival time after 
diagnosis was shorter in people with any non­Alzheimer’s 
dementia than in people with Alzheimer’s disease (MD 
–1·12 years, 95% CI –1·52 to –0·72; figure 4). However, 
Figure 1: Study selection
11 973 records identified through database searching 
10 655 records after duplicates removed
462 full-text records assessed for eligibility
78 studies included in the systematic review and 
meta-analysis
1318 duplicated records excluded
10 193 excluded by title and abstract
384 excluded
27 review or meta-analysis or 
comment
117 no death data from onset or 
diagnosis
131 single-arm, no patients with 
Alzheimer's disease as  
comparator
54 population as all-cause dementia
22 same population
7 case-report or series
7 randomised controlled trials
6 pure pathology study
5 selected autopsy
7 studies discussing cause of death
1 inadequate raw data
All dementia AD VaD LBD FTLD
Sample size 63 125 46 314 10 799 4474 1538
Age at onset, years 68·1 (7·0) 68·8 (6·7) 67·5 (7·2) 72·4 (3·2) 58·6 (2·5)
Age at diagnosis, years 72·7 (5·9) 74·2 (5·7) 73·5 (7·0) 74·5 (2·5) 64·2 (3·2)
Age at death, years 77·6 (5·3) 78·6 (5·1) 77·0 (6·9) 79·1 (2·4) 68·2 (3·2)
Survival from onset, years 7·3 (2·3) 7·6 (2·1) 6·5 (1·2) 6·8 (2·5) 7·6 (2·9)
Survival from diagnosis, 
years
4·8 (2·0) 5·8 (2·0) 3·2 (1·4) 4·7 (1·8) 4·9 (2·2)
Data are given in n or mean (SD). AD=Alzheimer’s disease. FTLD=frontotemporal lobe degeneration. LBD=Lewy body 
dementia. VaD=vascular dementia.
Table 1: Summarised clinical characteristics of the included dementia types
Articles
www.thelancet.com/healthy-longevity   Published online July 20, 2021   https://doi.org/10.1016/S2666-7568(21)00140-9 5
the mean difference in survival time from diagnosis 
compared with Alzheimer’s disease was similar for 
vascular dementia (–1·33, –2·16 to –0·51), Lewy body 
dementia (–1·01, –1·53 to –0·50), and frontotemporal 
degeneration (–1·01, –1·95 to–0·08; group difference: 
p=0·80; figure 4). Among the subtypes of Lewy 
body dementia, Parkinson’s disease dementia was 
associated with the shortest survival time from diagnosis 
compared with the Alzheimer’s disease reference (–3·81; 
–5·26 to –2·37), but data were only available from 
two studies (n=83). Among the subtypes of fronto­
temporal degeneration, there was only one cohort study 
on behavioural variant frontotemporal dementia and one 
cohort study on semantic dementia available.
Survival time from disease onset in people with any 
non­Alzheimer’s dementia was shorter than survival 
time in those with Alzheimer’s disease (MD –0·85, 
95% CI –1·4 to –0·25; appendix p 56); however, this 
difference could not be replicated for each individual 
dementia subtype (only vascular dementia and dementia 
with Lewy bodies showed a significantly shorter survival 
time from disease onset than Alzheimer’s disease 
[appendix pp 57–64], maybe because of the small sample 
sizes).
In the Alzheimer’s disease group, the mean age at 
death was 78·6 years (5·1; table 1). The mean age at death 
in people with any non­Alzheimer’s dementia was lower 
than that of people with Alzheimer’s disease (MD –1·76, 
95% CI –2·67 to –0·85; figure 5). Compared with people 
with Alzheimer’s disease, people with frontotemporal 
degeneration had the lowest mean age at death, whereas 
people with vascular dementia did not show a significantly 
younger age at death (significant group differences 
between vascular dementia, Lewy body dementia, 
frontotemporal degeneration: p=0·03). All of the subtypes 
of Lewy body dementia and frontotemporal degeneration 
were associated with a younger age at death compared 
with Alzheimer’s disease. Furthermore, people with 
semantic dementia (MD –6·04, –10·69 to –1·39) had the 
youngest age at death compared with Alzheimer’s 
disease, although there were only two semantic dementia 
cohorts available (n=17; figure 5).
The results of meta­regression and subgroup analyses 
are reported in the appendix (pp 76–107) and summarised 
in table 2. For HR and RR outcomes of all­cause mortality, 
all changes in point estimates were less than 10% when 
adjusted for potential confounders. When adjusting for 
NOS scores, effect sizes of the comparisons of mean 
survival time from diagnosis between frontotemporal 
degeneration and Alzheimer’s disease changed from 
–1·02 (95% CI –1·95 to –0·10) to –1·17 (–1·72 to –0·02) 
with a change­in­estimate of 14·7% (0·15 of 1·02). Age was 
a significant moderator in four comparisons between non­
Alzheimer’s dementia types and Alzheimer’s disease, with 
more than 10% of change­in­estimate. Comparing the 
outcome for the age at death betweendementia with Lewy 
bodies and Alzheimer’s disease, the effect size changed 
from –1·61 (–2·80 to –0·42) to –1·34 (–2·45 to –0·23) with 
a change­in­estimate of 16·8% (0·27/1·61) when adjusted 
for differences in age at onset, and the effect size was 
changed from –1·61 (–2·80 to –0·42) to –1·99 (–3·35 to 
–0·64) with a change­in­estimate of 23·6% (0·38/1·61) 
when adjusted for difference in age at diagnosis. 
Comparing the outcome for age at death between non­
Alzheimer’s dementia (a group of non­specified Lewy body 
dementia, Parkinson’s disease dementia, and dementia 
with Lewy bodies) and Alzheimer’s disease, the effect size 
was changed from –1·74 (–2·81 to –0·66) to –1·21 (–2·51 to 
0·07) with a change­in­estimate of 30·5% (0·53/1·74) 
when adjusted for difference in age at onset; and the effect 
size was changed from –1·74 (–2·81 to –0·66) to –1·97 
(–3·25 to –0·70) with a change­in­estimate of 13·2% 
(0·23/1·74) when adjusted for difference in age at 
diagnosis. Sex was a significant moderator in the 
comparison of RR outcomes for all­cause mortality 
between vascular dementia and Alzheimer’s disease (effect 
size changed from 1·28 [1·13 to 1·45] to 1·22 [1·05 to 1·42]; 
change­in­estimate: 4·7% [0·06/1·28]) and in the age of 
death between non­Alzheimer’s disease dementia and 
Figure 2: HR of mortality for people with dementia versus controls
AD=Alzheimer’s disease. FTLD=frontotemporal lobe degeneration. HR=hazard ratio. LBD=Lewy body dementia. 
VaD=vascular dementia.
Figure 3: HR of mortality for people with non-AD dementia versus AD
AD=Alzheimer’s disease. bvFTD=behavioral variant frontotemporal dementia. DLB=dementia with Lewy bodies. 
FTLD=frontotemporal lobe degeneration. HR=hazard ratio. LBD=Lewy body dementia. NA=not applicable. 
nFTLD=not specified frontotemporal lobe degeneration. nLBD=not specified Lewy body dementia. 
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Alzheimer’s disease (effect size changed from –1·75 [–2·66 
to –0·85] to –1·75 [–2·54 to –0·96]; change­in­estimate: 0% 
[0·0/1·75; table 2). The subgroup analyses revealed that 
the survival time from diagnosis was not significant for 
dementia with Lewy bodies compared with Alzheimer’s 
disease and neither was it for a group of dementia with 
Lewy bodies and Lewy body variant of Alzheimer’s disease 
compared with Alzheimer’s disease in the cross­sectional 
studies (appendix pp 93–94).
Sensitivity analyses removing a single study at a 
time suggested that our study findings were robust 
(appendix pp 108–136). The funnel plots and Egger’s tests 
detected several small­study effects (appendix pp 137–165). 
We found larger effect sizes for smaller studies in 
HR (non­Alzheimer’s vs Alzheimer’s disease on 
appendix p 138; vascular dementia vs Alzheimer’s disease 
on appendix p 139; Lewy body dementia vs Alzheimer’s 
disease on appendix p 140), RR (all dementia vs controls 
on appendix p 143; Lewy body dementia vs Alzheimer’s 
disease on appendix p 146), and of age at death (fronto­
temporal degeneration vs Alzheimer’s disease on 
appendix p 162). Publication bias and small­study effects 
Figure 4: Differences in survival time from diagnosis for people with non-AD dementia versus AD
AD=Alzheimer’s disease. bvFTD=behavioral variant frontotemporal dementia. DLB=dementia with Lewy bodies. FTLD=frontotemporal lobe degeneration. LBD=Lewy 
body dementia. LBVAD=Lewy body variant of Alzheimer’s disease. NA=not applicable. nFTLD=not specified frontotemporal lobe degeneration. nLBD=not specified 
Lewy body dementia. PDD=Parkinson’s disease dementia. SD=semantic dementia. VaD=vascular dementia. 
Figure 5: Differences in age at death for people with non-AD dementia versus AD
AD=Alzheimer’s disease. bvFTD=behavioral variant frontotemporal dementia. DLB=dementia with Lewy bodies. FTLD=frontotemporal lobe degeneration. LBD=Lewy 
body dementia. LBVAD=Lewy body variant of Alzheimer’s disease. NA=not applicable. nFTLD=not specified frontotemporal lobe degeneration. nLBD=not specified 
Lewy body dementia. PDD=Parkinson’s disease dementia. SD=semantic dementia. VaD=vascular dementia.
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were not found in the outcomes of survival time from 
onset and diagnosis.
Discussion 
This meta­analysis compared the mortality rate and 
survival outcomes between individuals with Alzheimer’s 
disease, with non­Alzheimer’s dementias, and without 
dementia on the basis of all the available published 
evidence. The main findings are that people living with 
dementia showed a 5·90 times larger HR for all­cause 
mortality rate compared with individuals without 
dementia, and the HR for all­cause mortality increased to 
17·88 in people living with Lewy body dementia. With 
respect to the risk posed by different types of dementia, 
people living with non­Alzheimer’s dementia (all types 
grouped together) showed a 1·33 times greater HR for 
all­cause mortality and a 1·12 year shorter survival after 
diagnosis compared with people with Alzheimer’s 
disease, but there were no significant differences 
between the vascular dementia, Lewy body dementia, 
and frontotemporal degeneration subgroups. In brief, 
although Alzheimer’s disease is the most common type 
of dementia and has been reported to be one of the 
leading causes of mortality, it has better survival 
outcomes than non­Alzheimer’s dementias.
To date, most studies addressing mortality risk in 
people with dementia focused on individuals with 
Alzheimer’s disease versus individuals without dementia. 
Our study found that people living with Alzheimer’s 
disease had a 3·70 times larger HR for all­cause mortality 
compared with individuals without dementia, indicating 
that Alzheimer’s disease contributed to a shortened life 
expectancy. We further found that people living with 
Lewy body dementia had a 17·88 times greater HR 
for all­cause mortality compared with individuals 
without dementia and a 1·45 times greater HR for 
all­cause mortality compared with individuals with 
Alzheimer’s disease. The subtypes of Lewy body 
dementia (Parkinson’s disease dementia and dementia 
with Lewy bodies) were also associated with higher HRs 
for all­cause mortality against the Alzheimer’s disease 
reference, which strengthens the evidence of a poor 
prognostic profile in these neurodegenerative conditions. 
A previous meta­analysis indicated that the RR for 
all­cause mortality was 2·2 in people with Parkinson’s 
disease versus people without dementia, and the 
subgroup analysis showed that people with Parkinson’s 
disease dementia had a particularly high risk of mortality 
compared to people without dementia (RR 3·78, 95% CI 
2·06–6·92).23 A population­based cohort study suggested 
that part of the increased mortality risk in patients with 
Parkinson’s disease can be ascribed to their increased 
risk of developing dementia.24 Yet another previous study 
showed that the survival advantage of Alzheimer’s 
Outcome Moderator Effect size  
(95% CI)




Dementia vs controls Hazard ratio Newcastle-Ottawa Scale 5·90 (3·53 to 9·86) 5·95 (4·00 to 8·84) 0·8%
LBD vs AD Hazard ratio Newcastle-Ottawa Scale 1·46 (1·26 to 1·68) 1·54 (1·36 to 1·75) 6·2%
VaD vs AD Risk ratio Difference in female proportion 1·28 (1·13 to 1·45) 1·22 (1·05 to 1·42) 4·7%
FTLD vs AD Risk ratio Follow-up year 1·22 (0·96 to 1·55) 1·24 (1·00 to 1·53) 1·6%
Non-AD vs AD Survival from diagnosis Difference in age at diagnosis –1·12 (–1·52 to –0·72) –1·21 (–1·64 to –0·79) 8·4%
FTLD vs AD Survival from diagnosis Sample size –1·02 (–1·95 to –0·10) –1·06 (–1·83 to –0·29) 3·9%
FTLD vs AD Survival from diagnosis Difference in sample size –1·02 (–1·95 to –0·10) –1·04 (–1·78 to –0·31) 2·0%
FTLD vs AD Survival from diagnosis Newcastle-Ottawa Scale –1·02 (–1·95 to –0·10) –1·17 (–1·72 to –0·02) 14·7%
DLB plus LBVAD vs AD Survival from diagnosis Age at diagnosis –0·93 (–1·46 to –0·40) –0·97 (–1·55 to –0·39) 4·3%
Non-AD vs AD Age at death Female proportion –1·76 (–2·66 to –0·85) –1·75 (–2·54 to –0·96) 0%
Non-AD vs AD Age at death Age at onset –1·76 (–2·66 to –0·85) –1·80 (–2·60 to –1·01) 2·9%
Non-AD vs AD Age at death Difference in age at onset –1·76 (–2·66 to –0·85) –1·83 (–2·45 to –1·21) 4·6%
Non-AD vs AD Age at death Difference in age at diagnosis –1·76 (–2·66 to –0·85) –1·86 (–2·79 to –0·93) 6·3%
LBD vs AD Age at death Difference in age at onset –1·28 (–2·06 to –0·50) –1·16 (–1·92 to –0·39) 9·4%
LBD vs AD Age at death Newcastle-Ottawa Scale –1·28 (–2·06 to –0·50) –1·39 (–2·13 to –0·66) 8·6%
DLB vs AD Age at death Difference in age at onset –1·61 (–2·80 to –0·42) –1·34 (–2·45 to –0·23) 16·8%
DLB vs AD Age at death Difference in age at diagnosis –1·61 (–2·80 to –0·42) –1·99 (–3·35 to –0·64) 23·6%
DLB plus LBVAD vs AD Age at death Difference in age at onset –1·14 (–1·96 to –0·33) –1·15 (–1·92 to –0·39) 0·9%
nLBD plus PDD plus DLB 
vs AD
Age at death Difference in age at onset –1·74 (–2·81 to –0·66) –1·21 (–2·51 to 0·07) 30·5%
nLBD plus PDD plus DLB 
vs AD
Age at death Difference in age at diagnosis –1·74 (–2·81 to –0·66) –1·97 (–3·25 to –0·70) 13·2%
AD=Alzheimer’s disease. FTLD=frontotemporal lobe degeneration. LBD=Lewy body dementia. LBVAD=Lewy body variant of Alzheimer’s disease. nLBD=not specified Lewy 
body dementia. NOS=Newcastle-Ottawa Scale. VaD=vascular dementia.
Table 2: Summarised findings of meta–regression analyses 
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disease over dementia with Lewy bodies persisted after 
adjusting for age at onset, gender, comor bidity, and 
cognitive function.13 It has been reported that people with 
Alzheimer’s disease had a better prognosis than people 
with dementia with Lewy bodies.12 Moreover, psychosis is 
more common in people with dementia with Lewy 
bodies than in people with Alzheimer’s disease, resulting 
in increased mortality risk.12 Compared with people with 
Alzheimer’s disease, people with dementia with Lewy 
bodies are reported to have an accelerated cognitive 
decline, more comorbid conditions, greater health­care 
service use, and poorer quality of life, which leads to a 
higher mortality rate.14,25–28 Consequently, Lewy body 
dementia (including Parkinson’s disease dementia and 
dementia with Lewy bodies) was associated with a higher 
mortality rate and greater reduction in life expectancy 
compared with Alzheimer’s disease.
We found that compared with people with Alzheimer’s 
disease, people living with vascular dementia had a 
1·26 times larger HR for all­cause mortality and a 
1·33 year shorter survival time after diagnosis, whereas 
there were no significant differences in age at death. An 
increased occurrence of vascular risk factors28 and higher 
rates of circulatory­associated death29 have been 
implicated in the increased mortality risk and reduced 
life­span survival time in vascular dementia compared 
with Alzheimer’s disease.30 The high frequency of 
mortality from circulatory system diseases in vascular 
dementia might reflect that vascular dementia is part of a 
general cardiovascular disease.
In our study, frontotemporal degeneration was 
associated with a reduced life expectancy but not with 
an increased mortality rate compared with Alzheimer’s 
disease, although a higher mortality rate was observed 
when compared with individuals without dementia. A 
study published in 2021 reported that motor symptoms 
were associated with reduced survival in patients with 
frontotemporal degeneration, including parkinsonism, 
dystonia, and apraxia.31 Besides, rapid eating and 
dysphagia are common in patients with frontotemporal 
degeneration, and these symptoms might increase the 
risk of choking, aspiration pneumonia, and mortality.32 
Importantly, people with frontotemporal degeneration 
might have a younger age at onset and diagnosis than 
people with Alzheimer’s disease, and thereby the 
mortality rate after diagnosis might be attenuated during 
the follow­up period. For example, Gerritsen and 
colleagues33 studied people with young­onset dementia 
who experienced their first symptoms before the age of 
65 years and reported a longer survival time for people 
with fronto temporal degeneration than for people with 
Alzheimer’s disease. To date, studies investigating the 
survival out comes of frontotemporal degeneration and its 
subtypes are scarce. The comparison of mortality rate 
between frontotemporal degeneration is debated.
Thus, for survival time from diagnosis, age at diagnosis 
might be a moderator; for survival time from onset, age at 
onset might be the moderator. Our study indeed found 
significant interactions between age and several survival­
related outcomes. However, the interaction effects were 
only observed for particular types of non­Alzheimer’s 
dementias compared with Alzheimer’s disease. Moreover, 
most of the adjusted effect sizes on these outcomes had 
less than 10% of change­in­estimates. Importantly, the 
findings of mortality rate (HR and RR) were robust 
for all non­Alzheimer’s dementias versus Alzheimer’s 
disease, without significant age­related moderator effects. 
Furthermore, we did not find any small­study effects for 
the outcomes of survival time from onset and diagnosis. 
However, the interactions between age and mortality were 
significant for Lewy body dementia and its subtypes; the 
adjusted effect sizes for age at death had significant 
changes in point estimate when adjusted for age at onset 
or diagnosis (range 0·9–30·5%). Therefore, age at 
onset and diagnosis might play an important role in the 
difference in survival time between Lewy body dementia 
(or its subtypes) and Alzheimer’s disease.
This study has several limitations. First, the sample size 
and the number of eligible studies for some subtypes of 
Lewy body dementia and frontotemporal degeneration 
were limited; therefore, we could not detect a difference 
though a significant difference might have existed for 
some comparisons. Second, heterogeneity was high in 
most analyses. We addressed this issue by using random­
effects meta­analysis models as well as meta­regression 
and subgroup analyses. To further reduce heterogeneity, 
we did not include single­arm studies, and all the effect 
sizes were calculated against individuals without dementia 
or Alzheimer’s disease reference groups. We also 
estimated the adjusted effect sizes and the proportion of 
change in point estimates for the significant moderators. 
Third, the data on age at onset and survival time from 
disease onset might be subject to recall bias. Fourth, we 
examined the mortality rate and survival time at a single 
point of clinical diagnosis, and some cases of dementia 
might be underdiagnosed or diagnosed late. A single 
cutoff of mortality on a particular date might lose 
information about when patients die over time. Local 
variation in practice groups (in terms of diagnosis) might 
add uncertainty to our estimates. Further studies could 
pool the prevalence and incidence data or infer the survival 
differences between Alzheimer’s disease and non­
Alzheimer’s dementia. Fifth, in clinical studies, the 
diagnosis of dementia was based on clinical assessment, 
which lacks specificity. Patients with dementia might have 
co­pathologies of Alzheimer’s disease, Lewy bodies, or 
vascular lesions. Finally, we only included peer­reviewed 
studies published in English. Therefore, our analyses did 
not include grey literature (eg, government reports) that 
might report vital statistics on dementia mortality.
In this systematic review and meta­analysis, we 
comprehensively compared non­Alzheimer’s dementias 
with Alzheimer’s disease and with individuals without 
dementia. Non­Alzheimer’s dementias were associated 
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with higher mortality rates and shorter life expectancy 
than Alzheimer’s disease. Most of all, Alzheimer’s 
disease appeared to have the most favourable survival­
related outcomes, and Lewy body dementia appeared to 
have the highest mortality rates. Higher mortality rates 
might also imply a higher likelihood of morbidity and 
disability. Discovering potential sources of divergence in 
mortality risks for distinct dementia types is important 
both for physicians and policy makers to develop tailored 
treatment and rehabilitation programmes for different 
types of demen tia, and for patients and their families to 
facilitate future care planning. Further epidemiological 
research is warranted to investigate the specific risk 
factors of early mortality at different levels of morbidity 
across different types of dementia.
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